Agilent's Open Access Solutions
Agilent's open access solutions enable pharmaceutical scientists to accelerate discovery by simplifying the management of multiple LC/MS and NMR instruments.
Agilent’s Open Access Solutions
Work with Agilent to spend less time managing and more time analyzing. Agilent’s open access solutions enable pharmaceutical scientists to accelerate discovery by simplifying the management of multiple LC/MS and NMR instruments. New MassHunter Walkup Software allows analytical chemists to easily configure and maintain multiple mass spec instruments right from their desks, so they can spend more time doing other important work. Users get answers quickly with solutions that extend to any automated routine LC or LC/MS measurements. New Vnmr J 4 Persona Manager provides NMR facility managers with the best, most flexible platform for managing multiple users and spectrometers. Learn more, and register for a live webinar at www.agilent.com/chem/togetherpharma#openaccess
Company name: Agilent Technologies, Inc.
Website: www.agilent.com/chem/togetherpharma#openaccess
E-mail: contact_us@agilent.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
